Dima Raskolnikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dima Raskolnikov has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alexander C. Small
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Montefiore at 1250 Waters Place, Bronx, NY 10461
4 shared publications - Beth Edelblute
Departments of Urology and Nephrology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, USA
3 shared publications - Kara L. Watts
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine; Montefiore at 1250 Waters Place, Bronx, NY 10461
3 shared publications - Andrewe L. Baca
Departments of Urology and Nephrology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, USA
2 shared publications - Emily Hunt
Albert Einstein College of Medicine; 1300 Morris Park Avenue, Bronx, NY 10461
2 shared publications - Tyler Bergeron
Albert Einstein College of Medicine; 1300 Morris Park Avenue, Bronx, NY 10461
2 shared publications
Latest Publications
- Open Access
- 22 April 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-6
Ureteroscopy at ambulatory surgery centers can be safe for select high-risk patients
Purpose: To determine whether unhealthy patients undergoing ureteroscopy at an ambulatory surgery center are at high risk of emergency post-operative transfer to an inpatient setting. Methods: Records of 100 consecutive high-risk patients undergoing URS at a free-standing ambulatory surgery center (ASC) were reviewed. Patients were considered high-risk if their American Society of Anesthesiologists score (ASA) was ≥ 3. Perioperative risk was assessed using the Charlson Comorbidity Index (CCI) and the 5-factor Modified Frailty Index (mFI-5). Post-operative complications requiring emergent inpatient transfer on the day of surgery and complications within 30-days were recorded. Results: The median age for patients was 61.4 years (IQR: 54.7–68.4) and median BMI was 31.0 (IQR: 26.6–37.2). Common chronic illnesses were hypertension (74%), COPD (44%), diabetes (40%), and peripheral vascular disease (14%). All patients were considered high-risk by ASA score. By CCI, 28% of patients were high-risk, 23% were significant risk and 49% were mild risk, with median score of 3 (IQR 1–5). By mFI-5, 20% of patients were high-risk, with median score of 2 (IQR 1–2). No patient required emergent transfer on the day of surgery. Within 30 days postoperatively, 15 patients presented to the Emergency Department (ED) and 5 were admitted. mFI-5 and CCI were not predictive of ED visits. Conclusion: Selected high-risk patients with unfavorable ASA, mFI-5, and CCI undergoing URS within an ASC are unlikely to require emergent, post-operative transfer to an inpatient facility.
- 22 April 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-6
Open AccessUreteroscopy at ambulatory surgery centers can be safe for select high-risk patients
Purpose: To determine whether unhealthy patients undergoing ureteroscopy at an ambulatory surgery center are at high risk of emergency post-operative transfer to an inpatient setting. Methods: Records of 100 consecutive high-risk patients undergoing URS at a free-standing ambulatory surgery center (ASC) were reviewed. Patients were considered high-risk if their American Society of Anesthesiologists score (ASA) was ≥ 3. Perioperative risk was assessed using the Charlson Comorbidity Index (CCI) and the 5-factor Modified Frailty Index (mFI-5). Post-operative complications requiring emergent inpatient transfer on the day of surgery and complications within 30-days were recorded. Results: The median age for patients was 61.4 years (IQR: 54.7–68.4) and median BMI was 31.0 (IQR: 26.6–37.2). Common chronic illnesses were hypertension (74%), COPD (44%), diabetes (40%), and peripheral vascular disease (14%). All patients were considered high-risk by ASA score. By CCI, 28% of patients were high-risk, 23% were significant risk and 49% were mild risk, with median score of 3 (IQR 1–5). By mFI-5, 20% of patients were high-risk, with median score of 2 (IQR 1–2). No patient required emergent transfer on the day of surgery. Within 30 days postoperatively, 15 patients presented to the Emergency Department (ED) and 5 were admitted. mFI-5 and CCI were not predictive of ED visits. Conclusion: Selected high-risk patients with unfavorable ASA, mFI-5, and CCI undergoing URS within an ASC are unlikely to require emergent, post-operative transfer to an inpatient facility.
- Open Access
- 24 March 2025
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 1-7
Understanding the clinical genetics of kidney stone disease using the Natera Renasight panel
We aimed to characterize the underlying genetics of kidney stone disease (KSD) in an urban and diverse population using the Natera Renasight genetic panel. This was a single-center prospective study of high-risk KSD patients, defined as recurrent stone formers or those with a family history with KSD. Buccal saliva DNA samples were collected with the commercially available Natera Renasight genetic panel and were analyzed using next-generation sequencing. The panel assesses 385 kidney disease related genes, including 45 linked to KSD. One hundred eleven high-risk KSD patients were enrolled. The majority were female (56%) with a median age of 50 (IQR 39.5–59.5), compromising a diverse ethnic background with 62% Hispanic, 23% White and 11% Black. Patients had median 3 (IQR 2–5) lifetime stone episodes, and 41% had family history of KSD. Genetic analysis was possible for 105 patients (95%). Eight (8%) had positive tests with only one patient found to have a pathogenic mutation associated with KSD (SLC7A9, cystinuria). The other 7 positive tests included amyloidosis (TTR, N = 3), Alport syndrome (COL4A3, N = 2), polycystic kidney disease (PKD1, N = 1), and susceptibility to ESRD (APOL1, N = 1). Patients with positive tests were more likely to have chronic kidney disease (38% vs 5%, p < 0.01), gout (13% vs 1%, p = 0.02) and carbonate apatite stones (38% vs 7%, p < 0.01). Our study sheds light on genetic factors of KSD in a diverse patient population. The results suggest that KSD is unlikely monogenetic in nature, but is more likely due to a complex interplay of polygenetic and environmental influences. Genetic testing may be most useful in KSD patients with chronic kidney disease.
- 24 March 2025
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 1-7
Open AccessUnderstanding the clinical genetics of kidney stone disease using the Natera Renasight panel
We aimed to characterize the underlying genetics of kidney stone disease (KSD) in an urban and diverse population using the Natera Renasight genetic panel. This was a single-center prospective study of high-risk KSD patients, defined as recurrent stone formers or those with a family history with KSD. Buccal saliva DNA samples were collected with the commercially available Natera Renasight genetic panel and were analyzed using next-generation sequencing. The panel assesses 385 kidney disease related genes, including 45 linked to KSD. One hundred eleven high-risk KSD patients were enrolled. The majority were female (56%) with a median age of 50 (IQR 39.5–59.5), compromising a diverse ethnic background with 62% Hispanic, 23% White and 11% Black. Patients had median 3 (IQR 2–5) lifetime stone episodes, and 41% had family history of KSD. Genetic analysis was possible for 105 patients (95%). Eight (8%) had positive tests with only one patient found to have a pathogenic mutation associated with KSD (SLC7A9, cystinuria). The other 7 positive tests included amyloidosis (TTR, N = 3), Alport syndrome (COL4A3, N = 2), polycystic kidney disease (PKD1, N = 1), and susceptibility to ESRD (APOL1, N = 1). Patients with positive tests were more likely to have chronic kidney disease (38% vs 5%, p < 0.01), gout (13% vs 1%, p = 0.02) and carbonate apatite stones (38% vs 7%, p < 0.01). Our study sheds light on genetic factors of KSD in a diverse patient population. The results suggest that KSD is unlikely monogenetic in nature, but is more likely due to a complex interplay of polygenetic and environmental influences. Genetic testing may be most useful in KSD patients with chronic kidney disease.